Core Viewpoint - Collegium Pharmaceutical, Inc. is set to report its second quarter 2025 financial results on August 7, 2025, before market opening, followed by a live conference call at 8:00 a.m. ET [1]. Company Overview - Collegium Pharmaceutical is focused on becoming a leading, diversified biopharmaceutical company dedicated to improving the lives of individuals with serious medical conditions [3]. - The company has a strong portfolio in responsible pain management medications and has recently acquired Jornay PM, a treatment for ADHD, marking its entry into neuropsychiatry [3]. - Collegium's growth strategy emphasizes expanding its commercial portfolio, with Jornay PM identified as the primary growth driver, while maintaining disciplined capital deployment [3].

Core Viewpoint - Collegium Pharmaceutical, Inc. is set to report its first quarter 2025 financial results on May 8, 2025, followed by a live conference call and webcast [1]. Financial Reporting - The financial results will be released after market close on May 8, 2025 [1]. - A live conference call will take place at 4:30 p.m. ET on the same day [1]. Conference Call Details - To access the conference call, participants can dial (877) 407-8037 for U.S. calls or (201) 689-8037 for international calls, referencing the "Collegium Pharmaceutical Q1 2025 Earnings Call" [2]. - An audio webcast will be available on the Company's website, with a replay accessible approximately two hours after the event [2]. Company Overview - Collegium Pharmaceutical is focused on becoming a leading, diversified biopharmaceutical company aimed at improving the lives of individuals with serious medical conditions [3]. - The Company has a strong portfolio in responsible pain management medications and has recently acquired Jornay PM, a treatment for ADHD, marking its entry into neuropsychiatry [3]. - Collegium's strategy includes expanding its commercial portfolio, with Jornay PM identified as the primary growth driver, and maintaining disciplined capital deployment [3].